Multiple Sclerosis Trial, Recruiting NCT02433028 Sponsor: University Hospital, Basel, Switzerland Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT02433028
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with one of the following conditions: radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), relapsing-remitting Multiple Sclerosis (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), neuromyelitis optica spectrum disorder (NMOSD), or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) — if you are unsure which of these applies to you, confirm with your doctor or the trial site.
  • You are willing and able to attend hospital visits every 6 or 12 months for at least 5 years, with some flexibility in scheduling (within about 45 days of the planned date).
  • You are willing to give blood samples every 6 or 12 months, either during your hospital visit or close to it (within about 8 days).
  • You are willing to have an optional brain MRI scan once a year as part of the study.

Who may not be able to join:

  • There are no specific exclusion criteria listed for this trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jens Kuhle, MD, University Hospital, Basel, Switzerland

Phone: 0041612652525

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Basel, Switzerland
Registry
ClinicalTrials.gov
Start date
1 June 2012
Est. completion
1 January 2042

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Assessment of Expanded Disability Status Scale (EDSS); Assessment of the quality of life; Collection of serum and plasma (and, optional) cerebrospinal fluid samples; (Optional) Assessment of finger dexterity; (Optional) Electrophysiological assessment; (Optional) Laboratory tests; (Optional) Magnetic resonance imaging

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov